Sciwind

Sciwind is a commercial-stage biopharmaceutical company dedicated to addressing urgent medical needs in the field of weight management. It focuses on developing innovative drugs with proprietary intellectual property rights and achieving the global industrialization and commercialization of its products. The company’s headquarters is located in Hangzhou, with its R&D and domestic registration center in Beijing. Sciwind has established wholly-owned subsidiaries in Australia and the United States, responsible for overseas clinical development, international regulatory submissions, and business development (BD). Based on multiple core innovative R&D platforms, Sciwind has built a robust pipeline of innovative drug candidates at various stages of development, while proactively advancing clinical trials abroad. Its product, Xianyida® (Ecnoglutide Injection), has been approved by the National Medical Products Administration (NMPA) for marketing in China to control blood glucose levels in adult patients with type 2 diabetes. This makes it the world's first approved cAMP-biased GLP-1 receptor agonist. Another indication for long-term weight management in adult patients with overweight or obesity has been submitted for marketing approval in China and accepted. Sciwind’s entrepreneurial team, R&D pipeline, and development capabilities have gained recognition from numerous investment institutions. It has secured strategic investments from IDG Capital, Loyal Valley Capital, LYFE Capital, Legend Capital, Shiyu Capital, and Haibang Investment, providing effective financial support for the company’s long-term growth. With an open mindset, Sciwind vigorously promotes independent R&D while actively pursuing strategic partnerships. It seeks collaboration opportunities worldwide to introduce high-quality, first-class products and technologies that meet urgent clinical needs, aiming to make innovative drugs accessible to patients in need at reasonable prices as soon as possible.